Nanobiotix (NASDAQ:NBTX) Reaches New 52-Week High - Here's What Happened

Key Points

• Nanobiotix reached a new 52-week high of $10.70 during trading, closing at $10.55 after a significant increase from its previous close of $9.74.
• Institutional investors now own 38.81% of Nanobiotix's stock, with a recent purchase from Jane Street Group LLC adding 23,283 shares valued at approximately $73,000.
• The company's lead product candidate, NBTXR3, is in development for treating various types of cancers, including soft tissue sarcoma and non-small cell lung cancer.

Nanobiotix S.A. Sponsored ADR (NASDAQ:NBTX - Get Free Report)'s share price reached a new 52-week high during trading on Wednesday . The company traded as high as $10.70 and last traded at $10.55, with a volume of 101 shares. The stock had previously closed at $9.74.

Nanobiotix Stock Performance

The stock has a 50 day simple moving average of $7.85 and a 200 day simple moving average of $5.24.

Hedge Funds Weigh In On Nanobiotix

An institutional investor recently bought a new position in Nanobiotix stock. Jane Street Group LLC acquired a new position in shares of Nanobiotix S.A. Sponsored ADR (NASDAQ:NBTX - Free Report) during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm acquired 23,283 shares of the company's stock, valued at approximately $73,000. 38.81% of the stock is owned by institutional investors.

Nanobiotix Company Profile

Nanobiotix SA, a clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer.